Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could light therapy glasses help fight opioid cravings?

NCT ID NCT05459922

Symptom relief Sponsor: Arizona State University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 24, 2026 · Updated 1 time

Summary

This pilot study tested whether wearing bright light therapy glasses can improve sleep and reduce cravings in people being treated for opioid use disorder. Twenty-three adults on stable medication-assisted treatment (methadone or buprenorphine) with insomnia used either active or placebo light glasses for several weeks. The study focused on whether the treatment was feasible and acceptable, and looked for early signs of benefit on sleep, reward learning, and opioid craving.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Wearable bright light therapy device (Re-timer®)
What this could lead to
If it works, this could offer a simple, drug-free way to improve sleep and reduce opioid cravings for people in recovery.
What could go wrong
This is a very small pilot study (23 people) testing feasibility, not effectiveness. The results may not apply to everyone, and the placebo device looks identical, so blinding may be imperfect.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

23 people

The number who actually took part.

Started

Oct 2022

Finished

Feb 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * age between 18 and 65 * ability to speak, write, and read in English * past 2 weeks of insomnia as evidenced by Insomnia Severity Index (ISI) total score of ≥10 * enrolled in outpatient medication-assisted treatment for OUD (i.e., either methadone or buprenorphine treatment) * been in medication-assisted treatment for at least 3 months * at least one month of stable methadone or buprenorphine dose * have a smartphone Exclusion Criteria: * lifetime history of bipolar disorder or mania * current narcolepsy, sleep paralysis, or restless leg syndrome as assessed by medical history * history of seizure disorders/epilepsy * the STOP-Bang score for obstructive sleep apnea ≥ 5 * retinal pathology, history of eye surgery or taking photosensitizing medications (e.g., lithium, L-tryptophan) * current regular use of melatonin * have circumstances that would interfere with study participation (e.g., impending jail sentence) * previous experience with bright light therapy * working a night shift or traveling outside the Arizona time zone in the past month * pregnant, trying to get pregnant, or breastfeeding * currently wearing prescription glasses with blue-light protection

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Insomnia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

insomnia opiate dependence Parasomnias sleep disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Opioid-use disorder Sleep disturbance

Contacts and locations

Locations

  • Arizona State University

    Phoenix, Arizona, 85004, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.